Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Critical Care Medicine

ISSN

2220-3141

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Crit Care Med. Dec 9, 2025; 14(4): 103782
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.103782

Full Size Figure Download Figure

Figure 2 Nanoparticle tracking analysis of exosomes. FTLA: Fitted track length average.

Citation: Kabatas S, Civelek E, Savrunlu EC, Kaplan N, Akkoc T, Küçükçakır N, Bozkurt M, Karaöz E. Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury. World J Crit Care Med 2025; 14(4): 103782
URL: https://www.wjgnet.com/2220-3141/full/v14/i4/103782.htm
DOI: https://dx.doi.org/10.5492/wjccm.v14.i4.103782

Kabatas S, Civelek E, Savrunlu EC, Kaplan N, Akkoc T, Küçükçakır N, Bozkurt M, Karaöz E. Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury. World J Crit Care Med 2025; 14(4): 103782 [PMID: 41377533 DOI: 10.5492/wjccm.v14.i4.103782]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.